文献速递头颈外科

TNFRSF1A 基因多态性预测局部晚期头颈癌放射性口腔黏膜炎及治疗反应

TNFRSF1A (-135 T>C, rs767455) Polymorphism as a Predictor of Radiation Induced Oral Mucositis and Treatment Response in Locally Advanced Head and Neck Cancer Patients.
PubMed 文献 · Head Neck · 2026-04-08

该研究纳入50例接受IMRT(70 Gy/35次)联合每周顺铂(40 mg/m2)的局部晚期头颈鳞癌患者,检测TNFRSF1A -135 T>C(rs767455)基因型及血清TNF-α水平。结果发现C等位基因携带者严重口腔黏膜炎风险显著升高(OR=4.58,p=0.010),TT基因型与完全缓解相关(OR=7.00,p=0.002)且TNF-α中位水平更高(13.28 pg/mL,p=0.041),提示该多态性可作为个体化放疗的潜在生物标志物。

要点

  • C等位基因携带者严重口腔黏膜炎风险增高(OR=4.58,p=0.010)。
  • TT基因型与完全缓解相关(OR=7.00,p=0.002)。
  • TT基因型血清TNF-α中位水平更高(13.28 pg/mL,p=0.041)。

核心结论

  • TNFRSF1A -135 T>C多态性同时影响头颈鳞癌放疗毒性和疗效,C等位基因易感口腔黏膜炎,TT基因型预示良好结局。

研究设计与样本

  • 研究纳入50例接受IMRT(70 Gy/35次)联合每周顺铂(40 mg/m2)的局部晚期头颈鳞癌患者,治疗前采血行PCR-RFLP基因分型及ELISA检测血清TNF-α。

主要发现

  • 基因型分布为TT 52.0%、TC 38.0%、CC 10.0%。
  • C等位基因携带者(TC/CC)严重口腔黏膜炎风险显著升高(OR=4.58,p=0.010),与皮炎无关联。
  • TT基因型与完全缓解相关(OR=7.00,p=0.002),且血清TNF-α中位水平更高(13.28 pg/mL,p=0.041)。
  • 多因素分析证实TNFRSF1A基因型为黏膜炎和疗效的独立预测因素,年龄对皮炎有保护作用。
  • 随机森林模型预测治疗反应的准确率为60%。

临床怎么用

  • 治疗前可考虑检测TNFRSF1A -135 T>C基因型,辅助识别严重口腔黏膜炎高危患者并预判放疗反应。

局限性

  • 样本量仅50例,结论需在更大队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) is the most common head and neck cancer in India, where intensity-modulated radiation therapy (IMRT) is the standard treatment. Despite therapeutic advances, variability in radiation response and toxicities persists. Genetic factors, including the TNFRSF1A (-135 T>C, rs767455) polymorphism, may influence susceptibility to oral mucositis, dermatitis, and treatment response, but remain insufficiently studied in Indian populations. Functional validation through serum TNF-α profiling and predictive modeling is also lacking. METHODS: A total of 50 patients with locally advanced HNSCC were treated with IMRT (70 Gy/35 fractions) and weekly cisplatin (40 mg/m2). Pre-treatment blood samples were analyzed for TNFRSF1A genotyping (PCR-RFLP) and serum TNF-α levels (ELISA). Oral mucositis and dermatitis were graded weekly using CTCAE v4.0, and treatment response was evaluated 90 days post-therapy by RECIST 1.1. Statistical analyses included Chi-square/Fisher's exact tests, odds ratios, Kruskal-Wallis ANOVA, and multivariate regression. A Random Forest model was applied for predictive evaluation. RESULTS: Genotype distribution was TT (52.0%), TC (38.0%), and CC (10.0%). Carriers of the C allele (TC/CC) had a significantly higher risk of severe mucositis (OR = 4.58, p = 0.010), while no association was observed with dermatitis. The TT genotype correlated with complete response (OR = 7.00, p = 0.002) and higher median serum TNF-α levels (13.28 pg/mL, p = 0.041). Multivariate analysis confirmed TNFRSF1A genotype as an independent predictor of mucositis and response, while age was protective against dermatitis. The Random Forest model achieved 60% accuracy in predicting treatment response. CONCLUSION: The TNFRSF1A (-135 T>C) polymorphism influences both toxicity and response in HNSCC, with the C allele predisposing to mucositis and the TT genotype predicting favorable outcomes. It represents a potential biomarker for personalized radiotherapy, meriting validation in larger cohorts.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Sarath Krishnan MP, Goyal B, Gupta S, et al. TNFRSF1A (-135 T>C, rs767455) Polymorphism as a Predictor of Radiation Induced Oral Mucositis and Treatment Response in Locally Advanced Head and Neck Cancer Patients. Head Neck. 2026. PMID: 41948912. doi:10.1002/hed.70277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。